NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD shares have increased by 48.2% and is now trading at $223.90. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

ABIOMED, Inc. (NASDAQ:ABMD) posted its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by $0.26. The medical equipment provider had revenue of $206.66 million for the quarter, compared to the consensus estimate of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. The business's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.60 earnings per share. View ABIOMED's earnings history.

8 brokers have issued 12 month price objectives for ABIOMED's shares. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's stock price to reach $193.00 in the next year. This suggests that the stock has a possible downside of 13.8%. View analysts' price targets for ABIOMED.

News headlines about ABMD stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABIOMED earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutABIOMED.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.37%), Primecap Management Co. CA (6.49%), Wellington Management Group LLP (6.39%), Baillie Gifford & Co. (6.05%), State Street Corp (4.43%) and Brown Capital Management LLC (3.64%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley and Michael R Minogue. View institutional ownership trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, William Blair Investment Management LLC, Franklin Resources Inc., Janus Henderson Group PLC, Primecap Management Co. CA, Morgan Stanley, Morgan Stanley, and Two Sigma Advisers LP. View insider buying and selling activity for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., BlackRock Inc., Baird Financial Group Inc., Global Thematic Partners LLC, Fred Alger Management LLC, Deutsche Bank AG, and TimesSquare Capital Management LLC. View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $223.90.

ABIOMED has a market capitalization of $10.07 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]